Cybin : C$70M in potential funding through a combination of the previously announced common share purchase agreement and current "at-the-market" equity program helps support upcoming clinical milestones - - Topline clinical data readouts expected in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 - Form 6-K
- C$70M in potential funding through a combination of the previously announced common share purchase agreement and current "at-the-market" equity program helps support upcoming... | June 8, 2023
Source: marketscreener.com